International journal publishes study exploring Uronext® properties to protect urinary tract

In its January issue, EC Gynaecology[1], an international scientific journal, published the data from a study investigating how effective the complex product Uronext® was in protecting the urinary tract. The study showed positive findings: female patients in the Uronext® group significantly less often experienced recurrent cystitis and reported an improved quality of life as compared to the control group.

Uronext® is the optimal combination of cranberry extract, D-mannose and vitamin D3, which is used to protect the urinary tract in adults and children over 7 years of age.

Dmitry Pushkar, Chief External Urologist of the Russian Ministry of Health, Professor, Academician of the Russian Academy of Sciences, led the team of Russian researchers to complete the study. Doctors investigated Uronext® to determine its efficacy, safety of use and ability to prevent exacerbations of cystitis in the future during a 3-month follow-up period.

This prospective parallel open-label study involved 111 female patients aged 18 to 80 with acute cystitis. The women were divided into 2 groups: one taking a standard single dose of antibiotics (fosfomycin trometamol), the other group was treated with a single dose of fosfomycin + Uronext® under the regimen of 1 sachet once per day for 7 days, followed by a 7-days break, then treatment repeated for 3 months (6 courses in total).

In 12 weeks after the start, the Uronext® group had 4 times more recurrent cystitis-free patients compared to the control group: 77.6 % vs. 19.2 %, respectively.

The ACSS questionnaire and the VAS scale revealed that the quality of life significantly improved for the Uronext® group patients throughout the study as compared to the control group. The authors of the study note that Uronext, when regularly used for 3 months, offers a safe and effective method of treatment and prevention for patients with lower urinary tract infections with no negative side effects.

Uncomplicated urinary tract infections are considered the most common bladder diseases in women. These infections recur, becoming chronic and make the lives of patients significantly more difficult. Every year, specialists register 26 to 36 million cases of patients with cystitis in Russia[2]. Cystitis most commonly occurs in female patients aged 25 to 30 and postmenopausal women over 55 years old. It is a well-known fact that acute or recurrent cystitis accounts for 60 % urology visits[3],[4].

Antibiotic therapy for urinary tract infections is one of the treatment methods; however, researchers today keep looking for alternative therapy options as pathogens exhibit more and more antimicrobial resistant properties.

Russian and international experts note that the regular prevention of bladder infections helps avoid the development of chronic diseases and complications. The Uronext® complex contains the special cranberry extract Cran-Max, 2,000 mg of D-mannose and 500 IU of vitamin D3, which act to prevent bacteria from attaching to the urinary tract epithelium[5], have antimicrobial and diuretic effects and support the local immunity. In addition, Uronext® is presented in a convenient dosage form for patients to use (only 1 sachet per day) and has a pleasant taste.

The study is registered in the database under number NCT05945667.


2 Loran O.B., Petrov S.B., Sinyakova L.A., Perepanova T.S. The effectiveness of the use of fosfomycin trometamol (Monurala 3 g) in the treatment of patients with chronic recurrent cystitis. Effective pharmacotherapy. Urology and Nephrology. 2008;4:14—16 (in Russ.).

3 Loran O.B. Chronic Cystitis in Women. In: Vrach (Doctor). — 1996. — No. 8. — Pp. 6–9.

4 Urology Manual / Ed. by N.A. Lopatkin. — Moscow: Meditsina Publishing House, 1998.

5 Armelle J. Cystites récidivantes: des moyens de prévention non médicamenteux [Recurrent cystitis: No medicine preventive means]. Prog Urol. 2017;27(14):823-830. doi:10.1016/j.purol.2017.09.006
Previous news

How to avoid getting sick during ARVI and influenza season: experts' opinion